Long-term aspirin use and the risk of total, high-grade, regionally advanced and lethal prostate cancer in a prospective cohort of health professionals, 1988-2006

International Journal of Cancer

Volumn 128, Issue 10, 2011, Pages 2444-2452

  Dhillon, Preet K ^a,b   Kenfield, Stacey A ^a,b   Stampfer, Meir J ^a,b   Giovannucci, Edward L ^a,b  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

aspirin; cancer; epidemiology; highgrade; lethal; NSAID; prostate; PSA

Indexed keywords

ACETYLSALICYLIC ACID; ANACIN; PROSTATE SPECIFIC ANTIGEN;

ADULT; ADVANCED CANCER; AGE DISTRIBUTION; AGED; ARTICLE; BODY MASS; BONE METASTASIS; CANCER MORTALITY; CANCER SCREENING; COHORT ANALYSIS; DIETARY INTAKE; DOSE RESPONSE; FAMILY HISTORY; GLEASON SCORE; HEALTH CARE PERSONNEL; HEALTH PRACTITIONER; HEART INFARCTION; HUMAN; LETHALITY; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; PHYSICAL ACTIVITY; PREDICTION; PRIORITY JOURNAL; PROSTATE CANCER; RISK ASSESSMENT; RISK FACTOR; RISK REDUCTION; SENSITIVITY ANALYSIS; SMOKING; TREATMENT DURATION;

ADULT; AGED; ANTICARCINOGENIC AGENTS; ASPIRIN; HEALTH PERSONNEL; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; PROSTATIC NEOPLASMS; UNITED STATES;

EID: 79953194117     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.25811     Document Type: Article

References (40)

1. Gupta S, Adhami VM, Subbarayan M, MacLennan GT, Lewin JS, Hafeli UO, Fu P, Mukhtar H,. Suppression of prostate carcinogenesis by dietary supplementation of celecoxib in transgenic adenocarcinoma of the mouse prostate model. Cancer Res 2004; 64: 3334-43. (Pubitemid 38581441)
2. Hsu AL, Ching TT, Wang DS, Song X, Rangnekar VM, Chen CS,. The cyclooxygenase-2 inhibitor celecoxib induces apoptosis by blocking Akt activation in human prostate cancer cells independently of Bcl-2. J Biol Chem 2000; 275: 11397-403. (Pubitemid 30212792)
3. Hussain T, Gupta S, Mukhtar H,. Cyclooxygenase-2 and prostate carcinogenesis. Cancer Lett 2003; 191: 125-35. (Pubitemid 36255597)
4. Lim JT, Piazza GA, Han EK, Delohery TM, Li H, Finn TS, Buttyan R, Yamamoto H, Sperl GJ, Brendel K, Gross PH, Pamukcu R, et al. Sulindac derivatives inhibit growth and induce apoptosis in human prostate cancer cell lines. Biochem Pharmacol 1999; 58: 1097-107. (Pubitemid 29381510)
5. Rotem R, Tzivony Y, Flescher E,. Contrasting effects of aspirin on prostate cancer cells: suppression of proliferation and induction of drug resistance. Prostate 2000; 42: 172-80. (Pubitemid 30080415)
6. Zhu W, Smith A, Young CY,. A nonsteroidal anti-inflammatory drug, flufenamic acid, inhibits the expression of the androgen receptor in LNCaP cells. Endocrinology 1999; 140: 5451-4.
7. Gonzalez-Perez A, Garcia Rodriguez LA, Lopez-Ridaura R,. Effects of non-steroidal anti-inflammatory drugs on cancer sites other than the colon and rectum: a meta-analysis. BMC Cancer 2003; 3: 28.
8. Mahmud S, Franco E, Aprikian A,. Prostate cancer and use of nonsteroidal anti-inflammatory drugs: systematic review and meta-analysis. Br J Cancer 2004; 90: 93-9. (Pubitemid 38174945)
9. Garcia Rodriguez LA, Gonzalez-Perez A,. Inverse association between nonsteroidal anti-inflammatory drugs and prostate cancer. Cancer Epidemiol Biomarkers Prev 2004; 13: 649-53. (Pubitemid 38737903)
10. Jacobs EJ, Thun MJ, Bain EB, Rodriguez C, Henley SJ, Calle EE,. A large cohort study of long-term daily use of adult-strength aspirin and cancer incidence. J Natl Cancer Inst 2007; 99: 608-15. (Pubitemid 47073542)
11. Perron L, Bairati I, Moore L, Meyer F,. Dosage, duration and timing of nonsteroidal antiinflammatory drug use and risk of prostate cancer. Int J Cancer 2003; 106: 409-15. (Pubitemid 36870405)
12. Habel LA, Zhao W, Stanford JL,. Daily aspirin use and prostate cancer risk in a large, multiracial cohort in the US. Cancer Causes Control 2002; 13: 427-34. (Pubitemid 34666598)
13. Jacobs EJ, Rodriguez C, Mondul AM, Connell CJ, Henley SJ, Calle EE, Thun MJ,. A large cohort study of aspirin and other nonsteroidal anti-inflammatory drugs and prostate cancer incidence. J Natl Cancer Inst 2005; 97: 975-80. (Pubitemid 41430563)
14. Norrish AE, Jackson RT, McRae CU,. Non-steroidal anti-inflammatory drugs and prostate cancer progression. Int J Cancer 1998; 77: 511-5. (Pubitemid 28340895)
15. Badawi AF,. The role of prostaglandin synthesis in prostate cancer. BJU Int 2000; 85: 451-62. (Pubitemid 30142622)
16. Betts WH, Whitehouse MW, Cleland LG, Vernon-Roberts B,. In vitro antioxidant properties of potential biotransformation products of salicylate, sulphasalazine and amidopyrine. J Free Radic Biol Med 1985; 1: 273-80. (Pubitemid 16117021)
17. Upchurch Jr SGR, Ramdev N, Walsh MT, Loscalzo J,. Prothrombotic consequences of the oxidation of fibrinogen and their inhibition by aspirin. J Thromb Thrombolysis 1998; 5: 9-14. (Pubitemid 28075248)
18. Maier TJ, Schilling K, Schmidt R, Geisslinger G, Grosch S,. Cyclooxygenase-2 (COX-2)-dependent and -independent anticarcinogenic effects of celecoxib in human colon carcinoma cells. Biochem Pharmacol 2004; 67: 1469-78. (Pubitemid 38388209)
19. Eibl G, Reber HA, Wente MN, Hines OJ,. The selective cyclooxygenase-2 inhibitor nimesulide induces apoptosis in pancreatic cancer cells independent of COX-2. Pancreas 2003; 26: 33-41. (Pubitemid 36020264)
20. Yamaguchi K, Lee SH, Eling TE, Baek SJ,. Identification of nonsteroidal anti-inflammatory drug-activated gene (NAG-1) as a novel downstream target of phosphatidylinositol 3-kinase/AKT/GSK-3beta pathway. J Biol Chem 2004; 279: 49617-23. (Pubitemid 39577764)
21. Leitzmann MF, Stampfer MJ, Ma J, Chan JM, Colditz GA, Willett WC, Giovannucci E,. Aspirin use in relation to risk of prostate cancer. Cancer Epidemiol Biomarkers Prev 2002; 11: 1108-11. (Pubitemid 35192666)
22. Rimm EB, Giovannucci EL, Stampfer MJ, Colditz GA, Litin LB, Willett WC,. Reproducibility and validity of an expanded self-administered semiquantitative food frequency questionnaire among male health professionals. Am J Epidemiol 1992; 135: 1114-26; discussion 1127-36.
23. Schroder FH, Hermanek P, Denis L, Fair WR, Gospodarowicz MK, Pavone-Macaluso M,. The TNM classification of prostate cancer. Prostate Suppl 1992; 4: 129-38.
24. Stampfer MJ, Willett WC, Speizer FE, Dysert DC, Lipnick R, Rosner B, Hennekens CH,. Test of the national death index. Am J Epidemiol 1984; 119: 837-9. (Pubitemid 14142821)
25. Giovannucci E, Rimm EB, Stampfer MJ, Colditz GA, Ascherio A, Willett WC,. Aspirin use and the risk for colorectal cancer and adenoma in male health professionals. Ann Intern Med 1994; 121: 241-6.
26. Chan AT, Ogino S, Fuchs CS,. Aspirin and the risk of colorectal cancer in relation to the expression of COX-2. N Engl J Med 2007; 356: 2131-42. (Pubitemid 47010839)
27. Chasan-Taber S, Rimm EB, Stampfer MJ, Spiegelman D, Colditz GA, Giovannucci E, Ascherio A, Willett WC,. Reproducibility and validity of a self-administered physical activity questionnaire for male health professionals. Epidemiology 1996; 7: 81-6. (Pubitemid 26003850)
28. Giovannucci E, Liu Y, Platz EA, Stampfer MJ, Willett WC,. Risk factors for prostate cancer incidence and progression in the health professionals follow-up study. Int J Cancer 2007; 121: 1571-8. (Pubitemid 47328718)
29. Moysich KB, Baker JA, Rodabaugh KJ, Villella JA,. Regular analgesic use and risk of endometrial cancer. Cancer Epidemiol Biomarkers Prev 2005; 14: 2923-8. (Pubitemid 43068826)
30. Viswanathan AN, Feskanich D, Schernhammer ES, Hankinson SE,. Aspirin, NSAID, and acetaminophen use and the risk of endometrial cancer. Cancer Res 2008; 68: 2507-13. (Pubitemid 351521827)
31. Mina K, Fritschi L, Johnson KC,. An inverse association between preserved fish and prostate cancer: results from a population-based case-control study in Canada. Nutr Cancer 2008; 60: 222-6. (Pubitemid 351451276)
32. Pham TM, Fujino Y, Kubo T, Ide R, Tokui N, Mizoue T, Ogimoto I, Matsuda S, Yoshimura T,. Fish intake and the risk of fatal prostate cancer: findings from a cohort study in Japan. Public Health Nutr 2008: 1-5.
33. Terry PD, Rohan TE, Wolk A,. Intakes of fish and marine fatty acids and the risks of cancers of the breast and prostate and of other hormone-related cancers: a review of the epidemiologic evidence. Am J Clin Nutr 2003; 77: 532-43. (Pubitemid 36258559)
34. Cuzick J, Otto F, Baron JA, Brown PH, Burn J, Greenwald P, Jankowski J, La Vecchia C, Meyskens F, Senn HJ, Thun M,. Aspirin and non-steroidal anti-inflammatory drugs for cancer prevention: an international consensus statement. Lancet Oncol 2009; 10: 501-7.
35. Dasgupta K, Di Cesar D, Ghosn J, Rajan R, Mahmud S, Rahme E,. Association between nonsteroidal anti-inflammatory drugs and prostate cancer occurrence. Cancer J 2006; 12: 130-5.
36. Roberts RO, Jacobson DJ, Girman CJ, Rhodes T, Lieber MM, Jacobsen SJ,. A population-based study of daily nonsteroidal anti-inflammatory drug use and prostate cancer. Mayo Clin Proc 2002; 77: 219-25. (Pubitemid 34177596)
37. Fowke JH, Motley SS, Smith JA, Jr, Cookson MS, Concepcion R, Chang SS, Byerly S,. Association of nonsteroidal anti-inflammatory drugs, prostate specific antigen and prostate volume. J Urol 2009; 181: 2064-70.
38. Andriole GL, Grubb RL, 3rd, Buys SS, Chia D, Church TR, Fouad MN, Gelmann EP, Kvale PA, Reding DJ, Weissfeld JL, Yokochi LA, Crawford ED, et al. Mortality results from a randomized prostate-cancer screening trial. N Engl J Med Engl 2009; 360: 1310-9.
39. Schroder FH, Hugosson J, Roobol MJ, Tammela TL, Ciatto S, Nelen V, Kwiatkowski M, Lujan M, Lilja H, Zappa M, Denis LJ, Recker F, et al. Screening and prostate-cancer mortality in a randomized European study. N Engl J Med 2009; 360: 1320-8.
40. Stark JR, Perner S, Stampfer MJ, Sinnott JA, Finn S, Eisenstein AS, Ma J, Fiorentino M, Kurth T, Loda M, Giovannucci EL, Rubin MA, et al. Gleason score and lethal prostate cancer: does 3 + 4 = 4 + 3? J Clin Oncol 2009; 27: 3459-64.